Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 19/20 | 0.74 |
| ▸ | MMP13 | P45452 | 17/20 | 0.74 |
| ▸ | ADAM17 | P78536 | 16/20 | 0.74 |
| ▸ | MMP14 | P50281 | 4/20 | 0.67 |
| ▸ | MMP1 | P03956 | 2/20 | 0.64 |
| ▸ | MMP9 | P14780 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3941501 | 0.96 | MMP2 (0.80) | MMP2MMP13ADAM17MMP14MMP1 | |
| SCHEMBL6265667 | 0.84 | ADAM17 (0.92) | MMP2MMP13ADAM17MMP14MMP1 | |
| SCHEMBL3948005 | 0.81 | ADAM17 (1.00) | MMP2MMP13ADAM17MMP14MMP1 | |
| SCHEMBL6835828 | 0.80 | MMP2 (0.53) | MMP2MMP13ADAM17MMP14MMP1 | |
| SCHEMBL6266477 | 0.78 | ADAM17 (0.85) | MMP2MMP13ADAM17MMP14MMP1 | |
| SCHEMBL7360883 | 0.78 | MMP2 (0.85) | MMP2MMP13ADAM17MMP14MMP1 | |
| SCHEMBL6267986 | 0.78 | ADAM17 (1.00) | MMP2MMP13ADAM17MMP14MMP1 | |
| SCHEMBL3937292 | 0.78 | ADAM17 (1.00) | MMP2MMP13ADAM17MMP14MMP1 | |
| SCHEMBL7394685 | 0.78 | ADAM17 (1.00) | MMP2MMP13ADAM17MMP14MMP1 | |
| SCHEMBL3948501 | 0.77 | ADAM17 (0.84) | MMP2MMP13ADAM17MMP14MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147085-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | WYETH CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6358980-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-03-19 | — | — | US | disclosed |